These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1279 related items for PubMed ID: 18376307

  • 1. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
    Xue A, Scarlett CJ, Jackson CJ, Allen BJ, Smith RC.
    Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
    [Abstract] [Full Text] [Related]

  • 2. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
    Warnecke-Eberz U, Prenzel KL, Baldus SE, Metzger R, Dienes HP, Bollschweiler E, Hoelscher AH, Schneider PM.
    Pancreas; 2008 Mar; 36(2):173-7. PubMed ID: 18376309
    [Abstract] [Full Text] [Related]

  • 3. Differential effects of fibroblast growth factors on expression of genes of the plasminogen activator and insulin-like growth factor systems by human breast fibroblasts.
    Sieuwerts AM, Martens JW, Dorssers LC, Klijn JG, Foekens JA.
    Thromb Haemost; 2002 Apr; 87(4):674-83. PubMed ID: 12008951
    [Abstract] [Full Text] [Related]

  • 4. Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction.
    Nielsen A, Scarlett CJ, Samra JS, Gill A, Li Y, Allen BJ, Smith RC.
    J Gastroenterol Hepatol; 2005 Feb; 20(2):256-63. PubMed ID: 15683429
    [Abstract] [Full Text] [Related]

  • 5. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
    Zhou Q, Liang LJ, Peng BG, Zhen YY.
    Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
    [Abstract] [Full Text] [Related]

  • 6. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A, Xue M, Jackson C, Smith RC.
    Int J Biochem Cell Biol; 2009 Nov; 41(8-9):1731-8. PubMed ID: 19433314
    [Abstract] [Full Text] [Related]

  • 7. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
    Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H, Manabe T.
    BMC Cell Biol; 2006 Feb 20; 7():8. PubMed ID: 16504015
    [Abstract] [Full Text] [Related]

  • 8. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan 20; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 9. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V, Schroeder J, Denkert C, Kristiansen G, Schnorr D, Loening SA, Jung K, Staack A.
    Oncol Rep; 2004 Oct 20; 12(4):909-13. PubMed ID: 15375521
    [Abstract] [Full Text] [Related]

  • 10. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
    Foca C, Moses EK, Quinn MA, Rice GE.
    Gynecol Oncol; 2000 Nov 20; 79(2):244-50. PubMed ID: 11063652
    [Abstract] [Full Text] [Related]

  • 11. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC, Holzscheiter L, Kotzsch M, Luther T, Kiechle-Bahat M, Sweep FC, Span PN, Schmitt M, Magdolen V.
    Int J Mol Med; 2008 Feb 20; 21(2):251-9. PubMed ID: 18204793
    [Abstract] [Full Text] [Related]

  • 12. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL.
    Gynecol Oncol; 2001 Jan 20; 80(1):48-55. PubMed ID: 11136569
    [Abstract] [Full Text] [Related]

  • 13. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, Ellis LM.
    Cancer Res; 2005 Sep 01; 65(17):7775-81. PubMed ID: 16140945
    [Abstract] [Full Text] [Related]

  • 14. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
    Bhuvarahamurthy V, Schroeder J, Kristiansen G, Roigas J, Denkert C, Johannsen M, Lein M, Loening SA, Schnorr D, Jung K, Staack A.
    Oncol Rep; 2005 Sep 01; 14(3):777-82. PubMed ID: 16077991
    [Abstract] [Full Text] [Related]

  • 15. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Danø K, Brünner N.
    Clin Cancer Res; 1997 Feb 01; 3(2):233-9. PubMed ID: 9815678
    [Abstract] [Full Text] [Related]

  • 16. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer.
    Minoo P, Baker K, Baumhoer D, Terracciano L, Lugli A, Zlobec I.
    Hum Pathol; 2010 Jan 01; 41(1):70-8. PubMed ID: 19740518
    [Abstract] [Full Text] [Related]

  • 17. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
    Leonardi A, Brun P, Sartori MT, Cortivo R, Dedominicis C, Saggiorato G, Abatangelo G, Secchi AG.
    Invest Ophthalmol Vis Sci; 2005 Apr 01; 46(4):1364-70. PubMed ID: 15790903
    [Abstract] [Full Text] [Related]

  • 18. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL.
    J Pathol; 2001 Sep 01; 195(2):236-43. PubMed ID: 11592104
    [Abstract] [Full Text] [Related]

  • 19. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J, Mizokami Y, Takahashi K, Nakajima K, Ohtsubo T, Miura S, Narasaka T, Takeyama H, Omata T, Shimokobe K, Ito M, Takehara H, Matsuoka T.
    Scand J Gastroenterol; 2005 Jul 01; 40(7):783-93. PubMed ID: 16109653
    [Abstract] [Full Text] [Related]

  • 20. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H.
    J Urol; 2005 Aug 01; 174(2):461-5. PubMed ID: 16006865
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.